Title
Cefiderocol dominates in vitro activity against Indian carbapenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Authors
Mallika Sengupta, Kshetrimayum Ammy, Indranil Banik, Shiv Sekhar Chatterjee, Ujjala Ghoshal & Sayantan Banerjee*
Affiliation
Department of Microbiology, All India Institute of Medical Sciences, Kalyani, West Bengal, India; *Corresponding author
Mallika Sengupta - E-mail: mallika.micro@aiimskalyani.edu.in
Kshetrimayum Ammy - E-mail: kshetrimayum.micro_pgt23@aiimskalyani.edu.in
Indranil Banik - E-mail: indranilbanikindia@gmail.com
Shiv Sekhar Chatterjee - E-mail: shivsekhar.micro@aiimskalyani.edu.in
Ujjala Ghoshal - E-mail: ujjala.micro@aiimskalyani.edu.in
Sayantan Banerjee - E-mail: sayantan.micro@aiimskalyani.edu.in
Article Type
Research Article
Date
Received July 1, 2026; Revised July 31, 2026; Accepted July 31, 2026, Published July 31, 2026
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and Acinetobacter baumannii (CRAB) are increasingly common in India, where treatment options remain largely limited to polymyxins, necessitating evaluation of newer therapeutic agents. In this prospective study, 11 CRPA and 29 CRAB isolates were characterized to determine carbapenem resistance mechanisms and in vitro activity of cefiderocol, aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, eravacycline and colistin was determined. Phenotypic metallo-β-lactamase production was detected in 64% of CRPA and 96% of CRAB isolates, while blaNDM was identified in 82% and 93% of CRPA and CRAB isolates. Cefiderocol demonstrated the highest in vitro activity, with susceptibility in all CRPA isolates and 86.2% of CRAB isolates, whereas imipenem-relebactam, meropenem-vaborbactam and eravacycline showed limited activity. Thus, data shows the cefiderocol was the most promising therapeutic option against carbapenem-resistant P. aeruginosa and A. baumannii in this Indian cohort, highlighting the urgent need to improve its clinical availability.
Keywords
Aztreonam-avibactam, cefiderocol, colistin, eravacycline, imipenem-relebactam, meropenem-vaborbactam
Citation
Sengupta et al. Bioinformation 22(7): 3947-3953 (2026)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
